Featured Press Releases

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

ImmPACT Bio announces FDA clearance of its IND application for CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research

  • 05 Mar 2024

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and...

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline

VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline

  • VectorY Therapeutics
  • 11 Nov 2026
ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

ProBio Signs Exclusive Global Licensing Agreement with AbTis for Next-Generation ADC Development

  • ProBio Inc.
  • 10 Nov 2026
Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

  • Waters Corporation
  • 10 Nov 2026
Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

Bayer’s SUNHARBO® (asundexian) Receives FDA Approval for Stroke Risk Reduction

  • Bayer
  • 10 Nov 2026
Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

  • Tenpoint Therapeutics, Ltd.
  • 09 Nov 2026
BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

  • UCB
  • 09 Nov 2026

Most Popular
November   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.